News | February 23, 2026
Morepen Labs lands record Rs. 825 crore global CDMO contract
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Subscribe To Our Newsletter & Stay Updated
